AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10543556 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest (EVH)
Number of subjects: 100
Study 10543556 — intervention group
Group type: COMPARATOR
Intervention: Open saphenous vein harvest (OVH)
Number of subjects: 100
Study 8740511 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 2
Study 8740511 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 2
Study 8740511 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril with calmodulin
Number of subjects: 2
Study 8740511 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril with calmodulin
Number of subjects: 2
Study 8740511 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2
Study 2066762 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 200 mg/mq, doxorubicin 45 mg/mq, and cyclophosphamide 600 mg/mq (CAC)
Number of subjects: 164
Study 2066762 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 50 mg/mq, doxorubicin 45 mg/mq, and cyclophosphamide 600 mg/mq (PAC)
Number of subjects: 164
Study 6643398 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting neuroleptics (fluphenazine decanoate or flupenthixol decanoate)
Number of subjects: 41
Study 6643398 — intervention group
Group type: COMPARATOR
Intervention: Placebo (withdrawal of long-acting neuroleptics)
Number of subjects: 41
Study 31922425 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 47
Study 31922425 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/pemetrexed
Number of subjects: 47
Study 31922425 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent therapies
Number of subjects: 47
Study 31922425 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapies
Number of subjects: 47
Study 31021390 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fraction SBRT (12 Gy for ≥4-cm lesions or 16 Gy for <4-cm lesions)
Number of subjects: 160
Study 31021390 — intervention group
Group type: COMPARATOR
Intervention: MFRT (30 Gy in 10 fractions)
Number of subjects: 160
Study 27858223 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) levels assessed using the Physical Activity Questionnaire PAQ-A
Number of subjects: 143
Study 27858223 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Condition (PC) assessed using ALPHA-Fitness
Number of subjects: 143
Study 27858223 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived Barriers (PB) assessed using Self-Reported Barriers to Participation in Physical Activity questionnaire
Number of subjects: 143
Study 26840067 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Insulin Demand (FID) counting
Number of subjects: 26
Study 26840067 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate Counting (CC)
Number of subjects: 26
Study 23715264 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive‐behavioral stress management (CBSM) with guided imagery
Number of subjects: 150
Study 23715264 — intervention group
Group type: COMPARATOR
Intervention: Individual information condition with muscle relaxation
Number of subjects: 150
Study 22406012 — intervention group
Group type: EXPERIMENTAL
Intervention: Church-based nutrition program for African Americans including pastoral involvement, educational activities, church environmental changes, and peer counseling.
Number of subjects: 1033
Study 22406012 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 1033
Study 20664618 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX) 5g/day for 1 week, then 10g/day for 2 weeks
Number of subjects: 54
Study 20664618 — intervention group
Group type: COMPARATOR
Intervention: Control (skim milk powder) 5g/day for 1 week, then 10g/day for 2 weeks
Number of subjects: 54
Study 20664618 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX)
Number of subjects: 54
Study 20664618 — intervention group
Group type: COMPARATOR
Intervention: Control (skim milk powder)
Number of subjects: 54
Study 20664618 — intervention group
Group type: COMPARATOR
Intervention: PolyGlycopleX (PGX) and Control (skim milk powder)
Number of subjects: 54
Study 17625431 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2a (40 kDa) for 48 weeks
Number of subjects: 0
Study 17625431 — intervention group
Group type: COMPARATOR
Intervention: lamivudine for 4 years
Number of subjects: 0
Study 17625431 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2a (40 kDa) with adefovir for lamivudine-resistant patients
Number of subjects: 0
Study 15798683 — intervention group
Group type: COMPARATOR
Intervention: 0 FRL (no ferrule, cast dowel/core and crown)
Number of subjects: 50
Study 15798683 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5/2 FRL (nonuniform ferrule, cast dowel/core and crown)
Number of subjects: 50
Study 15798683 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 FRL (2 mm ferrule, cast dowel/core and crown)
Number of subjects: 50
Study 15798683 — intervention group
Group type: EXPERIMENTAL
Intervention: CRN (no root canal treatment, restored with a crown)
Number of subjects: 50
Study 15798683 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT/CRN (RCT treated tooth with a crown alone)
Number of subjects: 50
Study 12020184 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 7705
Study 12020184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study 9498640 — intervention group
Group type: EXPERIMENTAL
Intervention: [N(ε)‐palmitoyl Lys (B29)] human insulin
Number of subjects: 9
Study 9498640 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 9
Study 7624200 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric induction segment
Number of subjects: 0
Study 7624200 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction segment at eccentric position
Number of subjects: 0
Study 7624200 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction effect
Number of subjects: 0
Study 7624200 — intervention group
Group type: EXPERIMENTAL
Intervention: Short segment position within one half-field
Number of subjects: 0
Study 1536410 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 40
Study 1536410 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with suxamethonium
Number of subjects: 40
Study 6375800 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental phenolization
Number of subjects: 103
Study 6375800 — intervention group
Group type: COMPARATOR
Intervention: Wedge excision
Number of subjects: 103
Study 31828753 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive intravenous (IV) fluid therapy
Number of subjects: 0
Study 31828753 — intervention group
Group type: COMPARATOR
Intervention: Standard-care intravenous (IV) fluid therapy
Number of subjects: 0
Study 29254987 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors (DPP‐4is)
Number of subjects: 67
Study 27373605 — intervention group
Group type: EXPERIMENTAL
Intervention: Onoact® 50 Lyophilized powder (50mg)
Number of subjects: 12
Study 27373605 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapibloc® concentrate IV (20mg/2mL)
Number of subjects: 12
Study 27373605 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 12
Study 27373605 — intervention group
Group type: COMPARATOR
Intervention: Concentrate formulation
Number of subjects: 12
Study 25287144 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin (30 µg/kg per day)
Number of subjects: 1161
Study 25287144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1161
Study 25287144 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Serelaxin and Placebo)
Number of subjects: 1161
Study 21659904 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonalcoholic beer (NAB) 1-1.5 L · d(‐1) for 3 weeks before and 2 weeks after the marathon
Number of subjects: 277
Study 21659904 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) beverage
Number of subjects: 277
Study 20427111 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 17
Study 20427111 — intervention group
Group type: COMPARATOR
Intervention: No visual feedback
Number of subjects: 17
Study 18019463 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for medial soft tissue release based on kinematic data
Number of subjects: 81
Study 18019463 — intervention group
Group type: COMPARATOR
Intervention: Surgeon's experience in making medial releases
Number of subjects: 81
Study 16075782 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive protocol (15 successive exposure nights)
Number of subjects: 14
Study 16075782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent protocol (3x 5 successive exposure nights, interspersed with 2 normoxic nights)
Number of subjects: 14
Study 12118866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast sensitivity measurements for letter stimuli of 2 sizes and 2 durations.
Number of subjects: 68
Study 12118866 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated cataracts on dynamic contrast sensitivity.
Number of subjects: 68
Study 9210061 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (tretinoin) at 120 or 150 mg/m2/day for 3 weeks followed by 1 week of rest, given as a single agent.
Number of subjects: 36
Study 8357360 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet
Number of subjects: 18
Study 8357360 — intervention group
Group type: COMPARATOR
Intervention: Reference diet
Number of subjects: 18
Study 3620293 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam (10 mg)
Number of subjects: 27
Study 3620293 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (30 mg)
Number of subjects: 27
Study 3620293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 29455212 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic glomerulonephritis (CGN) group
Number of subjects: 64
Study 29455212 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-risk pregnancies without CKD)
Number of subjects: 64
Study 27221567 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2.5 (150 μg/m(3))
Number of subjects: 0
Study 27221567 — intervention group
Group type: COMPARATOR
Intervention: Filtered Air (FA)
Number of subjects: 0
Study 27221567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (240 μg/m(3))
Number of subjects: 0
Study 27221567 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2.5 plus Ozone
Number of subjects: 0
Study 24366937 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg orally daily for 2 years
Number of subjects: 835
Study 24366937 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 835
Study 24366937 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib with positive FISH EGFR score
Number of subjects: 835
Study 22826980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 81
Study 20565202 — intervention group
Group type: EXPERIMENTAL
Intervention: Group voice in decision-making procedures (equal opportunities for interest groups to express opinions)
Number of subjects: 0
Study 20565202 — intervention group
Group type: COMPARATOR
Intervention: No voice procedures (unilateral decision-making)
Number of subjects: 0
Study 20565202 — intervention group
Group type: COMPARATOR
Intervention: Unequal group-voice procedures (one interest group receives voice, another does not)
Number of subjects: 0
Study 20565202 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual's own level of knowledge about CCS
Number of subjects: 0
Study 19065853 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractal patterns with a fractal dimension of 1.3
Number of subjects: 0
Study 19065853 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractal patterns with different fractal dimensions
Number of subjects: 0
Study 15667494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 2 mg b.i.d.
Number of subjects: 1264
Study 15667494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d.
Number of subjects: 1264
Study 15667494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1264
Study 12839848 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy with FLAC/granulocyte-colony-stimulating factor
Number of subjects: 53
Study 12839848 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy
Number of subjects: 53
Study 10663415 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion 300 mg/day
Number of subjects: 91
Study 10663415 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion 150 mg/day
Number of subjects: 91
Study 10663415 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 91
Study 8797405 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid inspiration without an end‐inspiratory pause
Number of subjects: 15
Study 8797405 — intervention group
Group type: COMPARATOR
Intervention: Slow inspiration with a 4‐s end‐inspiratory pause
Number of subjects: 15
Study 1556626 — intervention group
Group type: EXPERIMENTAL
Intervention: Three Knowles pins
Number of subjects: 6
Study 1556626 — intervention group
Group type: COMPARATOR
Intervention: Compression hip screw (CHS) and side plate
Number of subjects: 6
Study 4029413 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally implanted venous access systems
Number of subjects: 42
Study 29383896 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment + acupuncture therapy (observation group)
Number of subjects: 79
Study 29383896 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 79
Study 27798895 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tegafur/gimeracil/oteracil (S‐1)
Number of subjects: 0
Study 27798895 — intervention group
Group type: COMPARATOR
Intervention: Uracil‐tegafur/leucovorin (UFT/LV)
Number of subjects: 0
Study 25023200 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic alert system for acute kidney injury
Number of subjects: 2373
Study 22681551 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipido‐Colloid Technology‐Nano‐OligoSaccharide Factor (TLC‐NOSF) dressing
Number of subjects: 187
Study 22681551 — intervention group
Group type: COMPARATOR
Intervention: TLC dressing (control group)
Number of subjects: 187
Study 20658835 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally expressive writing (EMO; n = 31)
Number of subjects: 62
Study 20658835 — intervention group
Group type: COMPARATOR
Intervention: Control group writing about facts of diagnosis and treatment (CTL; n = 31)
Number of subjects: 62
Study 18209982 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive thymectomy (including robotic-assisted surgery)
Number of subjects: 0
Study 16022024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrabrush
Number of subjects: 110
Study 16022024 — intervention group
Group type: COMPARATOR
Intervention: Sonicare
Number of subjects: 110
Study 16022024 — intervention group
Group type: COMPARATOR
Intervention: Oral-B
Number of subjects: 110
Study 11805503 — intervention group
Group type: EXPERIMENTAL
Intervention: BioMask treatment with excimer laser phototherapeutic keratectomy (PTK)
Number of subjects: 22
Study 9916956 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot leuprolide (3.75 mg/mo)
Number of subjects: 100
Study 9916956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7583865 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfume inhalation from magazine scent strips
Number of subjects: 29
Study 7583865 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 29
Study 2305013 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.22 mg/70 kg
Number of subjects: 30
Study 2305013 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.43 mg/70 kg
Number of subjects: 30
Study 2305013 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.65 mg/70 kg
Number of subjects: 30
Study 2305013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 348535 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (10 mg t.d.s. for the first week, increasing to 20 mg t.d.s. for the subsequent three weeks)
Number of subjects: 106
Study 348535 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (25 mg t.d.s. for the first week, increasing to 50 mg t.d.s. for the subsequent three weeks)
Number of subjects: 106
Study 30167733 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher group
Number of subjects: 4248
Study 30167733 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4248
Study 30167733 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood % poverty
Number of subjects: 4248
Study 30167733 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing discrimination
Number of subjects: 4248
Study 28291862 — intervention group
Group type: EXPERIMENTAL
Intervention: Splinted prostheses with short implants (short group SP)
Number of subjects: 12
Study 28291862 — intervention group
Group type: COMPARATOR
Intervention: Nonsplinted prostheses with regular implants (regular group NSP)
Number of subjects: 12
Study 28291862 — intervention group
Group type: COMPARATOR
Intervention: Splinted prostheses with regular implants (regular group SP)
Number of subjects: 12
Study 28291862 — intervention group
Group type: COMPARATOR
Intervention: Nonsplinted prostheses with short implants (short group NSP)
Number of subjects: 12
Study 25761644 — intervention group
Group type: EXPERIMENTAL
Intervention: iPod touch device for stigma reduction intervention
Number of subjects: 0
Study 23164373 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol
Number of subjects: 100
Study 23164373 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine
Number of subjects: 100
Study 20497432 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (group I)
Number of subjects: 29
Study 20497432 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar triamcinolone orbital injection (group II)
Number of subjects: 29
Study 19047532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 5145
Study 19047532 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (control)
Number of subjects: 5145
Study 19047532 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (intensive lifestyle intervention and diabetes support and education)
Number of subjects: 5145
Study 16324269 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin inhalation cough challenge test by dosimeter method
Number of subjects: 91
Study 12826636 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of oral prednisone once daily for 10 days
Number of subjects: 147
Study 12826636 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 147
Study 10987447 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchy message counseling promoting male and female condoms, diaphragm, cervical cap, spermicides, and withdrawal.
Number of subjects: 3
Study 10987447 — intervention group
Group type: COMPARATOR
Intervention: Counseling about condoms only (control group).
Number of subjects: 3
Study 8651227 — intervention group
Group type: EXPERIMENTAL
Intervention: multiple vitamin/mineral supplement
Number of subjects: 3318
Study 8651227 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3318
Study 2052468 — intervention group
Group type: EXPERIMENTAL
Intervention: Volmax 8 mg orally every 12 hours for 3 days
Number of subjects: 23
Study 2052468 — intervention group
Group type: COMPARATOR
Intervention: Proventil Repetabs 8 mg orally every 12 hours for 3 days
Number of subjects: 23
Study 6861447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted group (group 1)
Number of subjects: 10
Study 6861447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed group (group 2)
Number of subjects: 10
Study 28903576 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (D1)
Number of subjects: 255
Study 28903576 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (D2)
Number of subjects: 255
Study 28903576 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 255
Study 28903576 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 255
Study 28903576 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 255
Study 28903576 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 255
Study 28091350 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavanone (HF; 70.5 mg) drink
Number of subjects: 40
Study 28091350 — intervention group
Group type: COMPARATOR
Intervention: Control drink (zero-flavanone)
Number of subjects: 40
Study 23713782 — intervention group
Group type: EXPERIMENTAL
Intervention: KOH 5% solution
Number of subjects: 29
Study 23713782 — intervention group
Group type: COMPARATOR
Intervention: KOH 2.5% solution
Number of subjects: 29
Study 23801093 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial immuno-enhancing supplement 5 days preoperatively
Number of subjects: 95
Study 23801093 — intervention group
Group type: COMPARATOR
Intervention: No supplements (Control)
Number of subjects: 95
Study 21602565 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma injection
Number of subjects: 54
Study 21602565 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) injection
Number of subjects: 54
Study 21602565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic examination
Number of subjects: 54
Study 18356109 — intervention group
Group type: EXPERIMENTAL
Intervention: 41.6 Gy in 13 fractions of 3.2 Gy
Number of subjects: 2236
Study 18356109 — intervention group
Group type: EXPERIMENTAL
Intervention: 39 Gy in 13 fractions of 3.0 Gy
Number of subjects: 2236
Study 18356109 — intervention group
Group type: COMPARATOR
Intervention: 50 Gy in 25 fractions of 2.0 Gy
Number of subjects: 2236
Study 17055945 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 256
Study 17055945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 14998080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous moxifloxacin 400 mg once-daily
Number of subjects: 49
Study 14998080 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral moxifloxacin 400 mg once-daily
Number of subjects: 49